James Wassil, MBA, MS, is the Business Unit Lead at Pfizer Vaccineswith responsibilities of Health Outcomes, Cost-Effectiveness, Market Access, Tender Procurement and Pricing.
James joined Pfizer in 2015 from Novartis, where he was Global Program Head for Meningococcal Vaccines and responsible for overseeing the development of Bexsero®, the company’s recently licensed meningococcal B vaccine and its ABCWY candidate vaccine. He also led the company’s US launch of Menveo®, a quadrivalent conjugate vaccine to protect against invasive disease caused by the ACWY serogroups of Neisseria meningitidis.
Mr. Wassil’s industry experience spans research, development, regulatory affairs, quality, technology transfer, and commercial operations. Prior to joining Novartis in 2008, he was with Merck for 16 years. He began his Merck career in technology transfer, where he helped to develop the company’s hepatitis A and rotavirus vaccines, and later played an integral role in significantly expanding international access to its vaccines serving as the representative to CVI.
Mr. Wassil earned a bachelor of science degree in chemistry/biology with high honors from the University of Notre Dame and a master of science degree in bio-organic chemistry and a master of business administration degree, both from Lehigh University. In 2014, James received the VIVA Award as Novartis’ top scientist in 2014 for development and approval of Bexsero®. He also was an ACE Finalist (Secretary of State Award for Corporate Excellence) for his role in conducting an effectiveness study of RotaTeq® in Nicaragua.